Literature DB >> 1867242

Risk factors for stroke in patients with nonrheumatic atrial fibrillation: a case-control study.

A W Moulton1, D E Singer, J S Haas.   

Abstract

PURPOSE: Randomized controlled trials have demonstrated that anticoagulant therapy is very effective at preventing stroke among patients with nonrheumatic atrial fibrillation. However, these trials have reported too few strokes for powerful risk factor analysis. Observational studies may provide additional information. The purpose of this study was to identify risk factors in a larger number of patients with stroke and nonrheumatic atrial fibrillation, using case-control methodology. PATIENTS AND METHODS: We identified all patients discharged from one hospital over an 8-year period who met our case definition of nonrheumatic atrial fibrillation and ischemic stroke (n = 134), and compared them with contemporaneous control subjects who were discharged with nonrheumatic atrial fibrillation without stroke (n = 131).
RESULTS: Cases and controls were similar in terms of duration of atrial fibrillation; proportion with paroxysmal atrial fibrillation; percentage with a past medical history of angina, myocardial infarction, congestive heart failure, diabetes, or smoking; and mean left atrial size. In contrast, cases were significantly older than controls (78.5 versus 74.8 years, p = 0.002) and more likely to have a history of hypertension (55% versus 38%, p = 0.0093). The relative odds for stroke was 1.91 for patients with hypertension, 1.73 for patients older than 75 years, and 3.26 for patients with both factors.
CONCLUSIONS: Our analysis suggests that age and hypertension should be considered when deciding upon long-term anticoagulant therapy to prevent stroke in patients with nonrheumatic atrial fibrillation.

Entities:  

Mesh:

Year:  1991        PMID: 1867242     DOI: 10.1016/0002-9343(91)90008-l

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  17 in total

Review 1.  Long-term anticoagulation therapy for atrial fibrillation in elderly patients: efficacy, risk, and current patterns of use.

Authors:  D McCormick; J H Gurwitz; R J Goldberg; J Ansell
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

2.  Stroke risk in AF: do AF patterns matter?

Authors:  Steven A Lubitz; Alisa B Rosen; Patrick T Ellinor; Emelia J Benjamin
Journal:  Eur Heart J       Date:  2010-03-18       Impact factor: 29.983

Review 3.  The role of coumadin and aspirin in atrial fibrillation.

Authors:  A M Hutter
Journal:  Trans Am Clin Climatol Assoc       Date:  1996

4.  Nonvalvular atrial fibrillation: evidence for a prothrombotic state.

Authors:  S R Kahn; S Solymoss; K M Flegel
Journal:  CMAJ       Date:  1997-09-15       Impact factor: 8.262

5.  Service provision and use of anticoagulants in atrial fibrillation.

Authors:  C M Sudlow; H Rodgers; R A Kenny; R G Thomson
Journal:  BMJ       Date:  1995-08-26

Review 6.  AF and Venous Thromboembolism - Pathophysiology, Risk Assessment and CHADS-VASc score.

Authors:  Nasir Shariff; Abdul Aleem; Mukesh Singh; Yuan Z Li; Stacey J Smith
Journal:  J Atr Fibrillation       Date:  2012-10-06

Review 7.  Challenges in the classification of atrial fibrillation.

Authors:  Steven A Lubitz; Emelia J Benjamin; Jeremy N Ruskin; Valentin Fuster; Patrick T Ellinor
Journal:  Nat Rev Cardiol       Date:  2010-06-22       Impact factor: 32.419

8.  Advanced age, low left atrial appendage velocity, and factor V promoter sequence variation as predictors of left atrial thrombosis in patients with nonvalvular atrial fibrillation.

Authors:  Dmitry A Zateyshchikov; Alexey N Brovkin; Dimitry A Chistiakov; Valery V Nosikov
Journal:  J Thromb Thrombolysis       Date:  2010-08       Impact factor: 2.300

Review 9.  A review of atrial fibrillation.

Authors:  David Dang; Raluca Arimie; L Julian Haywood
Journal:  J Natl Med Assoc       Date:  2002-12       Impact factor: 1.798

Review 10.  Clinical epidemiology of atrial fibrillation and related cerebrovascular events in the United States.

Authors:  Kamakshi Lakshminarayan; David C Anderson; Charles A Herzog; Adnan I Qureshi
Journal:  Neurologist       Date:  2008-05       Impact factor: 1.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.